Literature DB >> 10330378

Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox.

B E Sobel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10330378     DOI： 10.1161/01.cir.99.19.2496

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  25 in total

1.  Hypotheses, rationale, design, and methods for prognostic evaluation in type 2 diabetic patients with angiographically normal coronary arteries. The MASS IV-DM Trial.

Authors:  Whady Hueb; Neuza Lopes; Paulo R Soares; Bernard J Gersh; Eduardo Gomes Lima; Ricardo D Oliveira Vieira; Cibele Larrosa Garzillo; Rosa Rhami Garcia; Alexandre Costa Pereira; Celia Maria Strunz; Claudio Meneguetti; Jeane Tsutsui; Jose Parga; Pedro Lemos; Alexandre Hueb; Augusto Ushida; Raul Maranhão; Dalton A Chamone; Jose Af Ramires
Journal:  BMC Cardiovasc Disord       Date:  2010-09-29       Impact factor: 2.298

Review 2.  Percutaneous coronary intervention in diabetics.

Authors:  Juhana Karha; Deepak L Bhatt
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

3.  The determinants of plasma plasminogen activator inhibitor-1 levels differ for American and Japanese men aged 40-49.

Authors:  Tomoko Takamiya; Takashi Kadowaki; Wahid R Zaky; Hirotsugu Ueshima; Rhobert W Evans; Tomonori Okamura; Atsunori Kashiwagi; Yasuyuki Nakamura; Yoshiyuki Kita; Russell P Tracy; Lewis H Kuller; Akira Sekikawa
Journal:  Diabetes Res Clin Pract       Date:  2005-12-01       Impact factor: 5.602

Review 4.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

5.  Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells.

Authors:  Yoshiyuki Rikitake; James K Liao
Journal:  Circulation       Date:  2005-06-13       Impact factor: 29.690

6.  Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Burton E Sobel; Regina M Hardison; Saul Genuth; Maria M Brooks; Robert D McBane; David J Schneider; Richard E Pratley; Kurt Huber; Robert Wolk; Ashok Krishnaswami; Robert L Frye
Journal:  Circulation       Date:  2011-07-18       Impact factor: 29.690

7.  Epicardial adipose tissue density and volume are related to subclinical atherosclerosis, inflammation and major adverse cardiac events in asymptomatic subjects.

Authors:  Markus Goeller; Stephan Achenbach; Mohamed Marwan; Mhairi K Doris; Sebastien Cadet; Frederic Commandeur; Xi Chen; Piotr J Slomka; Heidi Gransar; J Jane Cao; Nathan D Wong; Moritz H Albrecht; Alan Rozanski; Balaji K Tamarappoo; Daniel S Berman; Damini Dey
Journal:  J Cardiovasc Comput Tomogr       Date:  2017-11-24

8.  Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells.

Authors:  Prachi Singh; Timothy E Peterson; Kara R Barber; Fatima Sert Kuniyoshi; Andrus Jensen; Michal Hoffmann; Abu S M Shamsuzzaman; Virend K Somers
Journal:  Biochem Biophys Res Commun       Date:  2010-01-05       Impact factor: 3.575

Review 9.  Should the insulin resistance syndrome be treated in the elderly?

Authors:  Richard W Grant; James B Meigs
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.

Authors:  Bernard R Chaitman; Regina M Hardison; Dale Adler; Suzanne Gebhart; Mary Grogan; Salvador Ocampo; George Sopko; Jose A Ramires; David Schneider; Robert L Frye
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.